News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Shanghai Institute of Materia Medica and Servier Collaborate on China Development for Cancer Drug



9/17/2013 3:07:15 PM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

by Richard Daverman, PhD

September 17, 2013 -- The Shanghai Institute of Materia Medica will collaborate with Servier, a French pharma, on China development of lucitanib, a clinical-stage anti-angiogenic cancer drug. SIMM will undertake research into biomarkers for the drug. The two companies plan to conduct China clinical trials of lucitanib in specific indications with the help of Haihe Pharmaceutical, a SIMM subsidiary. SIMM and Servier will own China rights to the drug jointly, though the China trial will be part of Servier’s larger effort to obtain global regulatory approval of lucitanib. More details....

Help employers find you! Check out all the jobs and post your resume.

Read at ChinaBio Today


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES